Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
This is Enzene Biosciences third biosimilar to be approved
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The company has to approach the DCGI for approval to commence the trials
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
Subscribe To Our Newsletter & Stay Updated
